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Abstract
Background: Myoclonus and tremor are common movement disorder phenomenologies in steroid-responsive encephalopathy associated with autoimmune
thyroiditis (SREAT). Pure ataxia without encephalopathy has rarely been reported.
Case report: We report 21- and 40-year-old females who presented with subacute pure ataxia without encephalopathy. After immunotherapies, both exhibited
initial improvement of ataxia, and subsequently remained in plateau phase.
Discussion: This treatable disorder should be added to the differential diagnoses of progressive cerebellar ataxia, and anti-thyroid peroxidase and anti-
thyroglobulin should be considered as part of the workup. It is crucial not to misdiagnose SREAT presenting with pure cerebellar ataxia as degenerative or
spinocerebellar ataxia.
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Introduction
Steroid-responsive encephalopathy with autoimmune thyroiditis
(SREAT), also called Hashimoto encephalopathy, has been a con-
troversial disorder in the literature.1–4 The term ‘‘non-vasculitic auto-
immune meningoencephalitis’’ has also been less commonly used.5
The main clinical presentation is encephalopathy; however, patients
may exhibit associated neurological features including seizures, move-
ment disorders such as myoclonus or tremor, and psychosis.3,6–9 Eleva-
tion of anti-thyroid antibodies, i.e. anti-thyroid peroxidase (anti-TPO or
anti-thyroid microsomal antibody) and/or anti-thyroglobulin (anti-Tg),
is required to make the diagnosis.10,11 Patients typically show good
response to immunotherapies, including steroids.7,12.
Uncommon movement disorder phenomenologies in SREAT include
ataxia without encephalopathy,13–19 chorea,20–22 and dystonia.22 Here,
we report two patients who presented with subacute onset of pure or
predominant cerebellar ataxia and negative autoimmune and para-
neoplastic workups, except anti-thyroid antibodies. The diagnosis could
easily have been mistaken for degenerative ataxia, such as spinocer-
ebellar ataxia, had this etiology not been searched for.
Case reports
Patient 1
The patient was a 21-year-old female with type 1 diabetes (onset at
age 15 years), treated with insulin, and hyperlipidemia. Her initial
presentation was walking difficulty that gradually worsened over
3 months. There were no cognitive complaints according to the patient
and her family. Examination revealed moderate-to-severe truncal ataxia.
Appendicular ataxia in bilateral arms and legs was also noted. There was
no evidence of overt encephalopathy on neurological examination;
however, formal neuropsychological testing and electroencephalography
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(EEG) were not performed. Eye movement examination revealed no
square wave jerks. On pursuit examination, there was mild left beating
gaze-evoked nystagmus on the extreme left gaze. No apparent saccadic
pursuits were observed. Saccade examination showed no slow or hyper-
metric saccades. There was no limitation in range of eye movements in
any direction. Deep tendon reflexes (DTRs) were all normal. There was
no pes cavus.
Investigations for autoimmune ataxia revealed positive anti-TPO
(1:1600, normal,1:100), and borderline positive anti-Tg (1:40,
normal,1:20). Thyroid function tests were unremarkable. Serum
anti-glutamic acid decarboxylase (anti-GAD) was negative. Serum
anti-nuclear antibody, and anti-Ro and anti-La antibodies were
negative. Serum ceruloplasmin was normal. Cerebrospinal fluid (CSF)
examination revealed protein 46 mg/dL, glucose 112 mg/dL (serum
glucose 196 mg/dL), white cells 1 per mm3, red cells 570 per mm3. CSF
oligoclonal bands, anti-aquaporin 4 (or anti-neuromyelitis optica),
and CSF paraneoplastic panel including anti-Hu (or anti-neuronal
nuclear antibody type 1 [ANNA-1]), anti-Ri (ANNA-2), anti-Yo (or anti-
Purkinje cell cytoplasmic antibody type 1 [PCA1]), anti-PCA2, anti-Tr,
anti-MAG (anti-myelin-associated glycoprotein), anti-Ma, anti-GAD,
anti-CV2/CRMP5, and anti-amphiphysin antibodies were all nega-
tive. Anti-gliadin and anti-tissue transglutaminase antibodies were
not tested. Magnetic resonance imaging (MRI) of the brain was normal,
and there was no evidence of cerebellar atrophy. Genetic testing for
Friedreich’s ataxia (FA) was not performed.
A 3-day course of intravenous methylprednisolone 1 g/day was
initiated, and led to marked improvement in her ataxia, which then
plateaued after a few weeks. The patient exhibited residual mild ataxia.
She continued on oral prednisone 1 mg/kg/day. With high-dose pre-
dnisone, she developed steroid-induced hyperglycemia with blood
sugar levels in the range between 200 and 300 mg/dL. This was
also co-managed by her endocrinologist. Prednisone was successfully
tapered very gradually, without exacerbation or worsening of ataxia.
She remained on 5 mg/day of oral prednisone. Her ataxia had
plateaued over the period of the 4-year follow-up without further
improvement or worsening (Video 1).
Patient 2
The second patient was a 40-year-old female with no known
underlying disease. She presented with progressive impairment of gait
and fine motor coordination of both hands over the time course of
6 months. There was no family history of ataxia or other movement
disorders. Her mental status was normal without any evidence of
encephalopathy. On examination, she was cognitively normal. She
could respond to all questions and commands appropriately. However,
formal neuropsychological testing and EEG were not performed. Her
speech was moderately slurred and had scanning quality. There was
moderate left dysmetria that was slightly greater than right dysmetria.
She walked with moderately wide-based ataxic gait. In addition to
ataxia, she also had mild dystonic posturing of both hands, the right
slightly greater than the left. Eye movement examination revealed mild
square wave jerks. Pursuits were normal. There was no limitation in
range of eye movements in any direction. Saccades were hypermetric
and more prominent in horizontal directions. There was no slowing of
saccades. DTRs were all normal. No pes cavus was observed.
Extensive investigations, including serum ceruloplasmin, urine
copper, and a serum paraneoplastic panel, were negative except for
positive serum anti-TPO (238.87 IU/mL, normal 0–5.61; note the
different laboratory from patient 1) and anti-Tg (57.35 IU/mL, normal
0–4.11) antibodies. A thyroid function test including thyroid stimulating
hormone (TSH), free thyroxine (FT4), and triiodothyronine (T3) was
normal. CSF examination revealed protein 40.8 mg/dL, glucose 63 mg/dL,
white cells 0 per mm3, and red cells 50 per mm3. CSF paraneoplastic
panel including anti-Hu (ANNA1), anti-Ri (ANNA-2), ANNA-3, anti-
GAD, anti-amphiphysin, anti-CV2/CRMP5, anti-NMDA receptor (anti-
N-methyl-D-aspartate receptor), anti-AMPA receptor, anti-GABA(B)
receptor and anti-VGKCC (anti-voltage-gated potassium channel
complex) were all negative. Anti-gliadin and anti-tissue transglutaminase
antibodies were not tested. MRI of the brain revealed no cerebellar
atrophy or other abnormalities. Genetic testing for common types of
spinocerebellar ataxia (SCA) in Thailand including SCAs 1, 2, and
3 were negative. Genetic testing for FA was not performed.
She was treated with a 3-day course of intravenous methylpredni-
solone 1 g/day, which led to slight improvement in her ataxia initially.
She was discharged with oral prednisone 1 mg/kg/day. After a gra-
dual moderate improvement over several weeks, her ataxia plateaued
and was stable at a mild-to-moderate degree. Tapering of the oral
prednisone was trialed but led to worsening of her ataxia. Despite
treatment with oral prednisone for 1.5 years, there was no further
improvement and the decision was made to start azathioprine as a
Video 1. This Video Shows Patient 1 after the Treatment. The exami-
nation was performed at age 25, 4 years after the onset of ataxia. At that time,
she was on prednisone 5 mg every other day. She had only very mildly slurred
and scanning speech. Eye movement examination revealed no square wave jerks.
There was no limitation of eye movements in any direction on both smooth
pursuit and saccade examination. There were no apparent saccadic or broken
pursuits. There was mild left beating gaze-evoked nystagmus on the extreme left
gaze. Saccades were normal. There was neither slowing of saccades nor
hypermetric saccade. Mild dysmetria and overshoot dysmetria, left greater than
right, were demonstrated on finger-to-nose-to-finger and finger following tests,
respectively. There was mild dysdiadochokinesia, which was more prominent
on the left. She was able to walk independently, but her gait was wide-based.
She had imbalance when standing with both feet together and eyes closed.
She required assistance when standing on only one foot, either left or right.
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steroid-sparing agent. During the last follow-up, she had been on
azathioprine 150 mg/day and a taper dose of prednisone. Her ataxia
had remained stable during the transitional period (Video 2).
Discussion
Our patients presented with subacute onset of cerebellar ataxia with
speech, trunk, and appendicular involvement. Movement disorders can
be manifestations of SREAT, and the common phenomenologies are
myoclonus, tremor, and ataxia.6,8 Dystonia and chorea have much less
commonly been reported in this rare entity.20–22 Although ataxia
(in combination with encephalopathy and other features) is not an uncom-
mon phenomenology in SREAT, there have been a limited number
of reports of patients with pure or predominant ataxia without encephalo-
pathy (Table 1). When ataxia is present as a sole or predominant feature,
the diagnosis can easily be missed or mistaken for degenerative ataxia.
Although this disorder has long been described, there remain several
controversial issues, including heterogeneity and the wide spectrum of
its clinical features (e.g. the absence of encephalopathy in some cases),
unclear association with thyroid disorders (since most patients are
euthyroid), appropriate nomenclature, non-specificity, and pathogenic
roles of anti-TPO and/or anti-Tg, as well as their correlations with
clinical severity.1–4 Anti-TPO and anti-Tg are common in the general
population and in patients with benign thyroid disorders without
any neurologic features.23 This can be a confounding factor in the
diagnosis of SREAT; therefore, the positivity of these antibodies
should be interpreted in the appropriate clinical context. In spite
of these controversies, clinical recognition of SREAT should not be
dismissed due to its treatable nature and generally good outcomes.
Our patients demonstrated improvement with steroids, as did
several cases previously reported in the literature.7,12 Patients may be
misdiagnosed with degenerative ataxia, especially spinocerebellar
ataxia, given an all negative extensive workup, as has occurred in
some reported cases with clinical features mimicking spinocerebellar
ataxia.16,17 Since this is a treatable entity, we propose the inclusion of
investigations for SREAT as a first or second tier in patients presenting
with subacute or even chronic progressive cerebellar ataxia, so that an
opportunity for treatment and improvement is not missed. Although
there are no systematic studies on treatment outcome in this rare
entity, amelioration of ataxia can potentially improve ambulatory
function and reduce disability in these patients.
While encephalopathy and various neurologic deficits such as
seizures, myoclonus, or psychosis are typical clinical features, many
patients without encephalopathy have been reported. Recently,
Miranda et al.22 reported two cases who presented with movement
disorders (one with myoclonus, dystonia, and ataxia, and the other
with choreoathetosis and dystonia) without encephalopathy, and
proposed the name, ‘‘non-encephalopathic Hashimoto’s thyroiditis’’.
Given the broadening spectrum of this entity and unclear/contro-
versial relationship with Hashimoto thyroiditis, we propose the name
‘‘anti-TPO/Tg antibody-related neurologic disorders responsive to
steroids (ATANDS)’’ to cover the entire spectrum of neurologic
disorders associated with these two antibodies. This should not only
avoid the confusion about encephalopathy and the association with
thyroid disorders, but also highlight the presence of anti-thyroid
antibodies and typically good response to steroids as its core features.
We performed a literature review of SREAT cases presenting with
pure ataxia or ataxia as a predominant feature, without encephalo-
pathy (Table 1). Similar to classic SREAT, patients with predominant
ataxia were mostly females (16/22 patients, female/male 8:3), and
euthyroid (20/22 patients, the other two had subclinical hypothyroid-
ism). Interestingly, two patients with predominant ataxia also had
saccadic intrusions (one with opsoclonus and one with ocular flutter).
Video 2. This Video Shows Patient 2 after the Treatment. The examination
was performed at age 40, 2 years after the onset of ataxia. She was on azathioprine
150 mg/day and a tapering dose of oral prednisone. The cerebellar features in this
patient were overall more prominent than in patient 1. Her speech was moderately
slurred and scanning. Eye movement examination demonstrated mild square wave
jerks. Pursuits were normal. There were hypermetric saccades, more prominent in
horizontal than vertical directions. There was no slowing of saccades or limitation
of eye movements in any direction. Mild dystonic posturing of both hands, right
slightly greater than left, was demonstrated. Finger-to-nose-to-finger test revealed
mild dysmetria, left greater than right. Finger following test demonstrated mild-to-
moderate overshoot dysmetria, left greater than right. Mild-to-moderate dysdia-
dochokinesia, left greater than right, was also demonstrated. She was able to walk
independently, but had wide-based gait. She was unable to stand with both feet
together without assistance, and had marked difficulty standing on only one foot.
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Time to diagnosis varied from 4 days to 120 months. Two patients
with relatively early (,1 month) diagnosis were the ones with saccadic
intrusions. When ataxia was more pure or with fewer prominent
additional features, the time to diagnosis tended to be delayed into
the subacute and chronic periods. All but one patient (21/22, 95%)
had positive anti-TPO antibody, while anti-Tg was elevated in 18 out
of 22 patients (82%). Eighteen patients (82%) were treated with
immunotherapies including steroids (almost all intravenous) and/
or intravenous immunoglobulin (IVIG). Two patients who initially
received steroids were switched to steroid-sparing agents: azathioprine
and mycophenolate mofetil in each patient. Seventeen of 18 patients
who received immunotherapies had improvement of variable degrees
(marked or excellent improvement in seven patients [34% of patients
treated with steroid]). Of note, the other one who did not improve with
immunotherapies received only oral steroids without any intravenous
treatment. Interestingly, two patients with delayed diagnosis (72 and
120 months) still had ‘‘good’’ response to immunotherapies. While the
analyses from previously reported cases provide some insights into the
clinical features and treatment outcome of pure or predominant ataxic
form of this disorder, these may be prone to biases. One limitation of
the present and previous retrospective studies was the lack of objective
assessment of ataxia, such as using the Scale for the Assessment and
Rating of Ataxia (SARA) or International Cooperative Ataxia Rating
Scale (ICARS) to evaluate treatment outcome. Future prospective studies
of this subtype of SREAT with incorporation of these standard rating
scales can be helpful, but may not be feasible given its rarity. Furthermore,
the true prevalence of this subtype is unknown. It is possible that this
subtype of SREAT is under-recognized, as it can easily be hidden among a
group of patients with ‘‘undiagnosed degenerative ataxia’’.
While SREAT can be misdiagnosed as degenerative ataxia, routine
tests for anti-TPO and anti-Tg in all patients with suspected degen-
erative ataxia may lead to false-positive results and overdiagnosis of
SREAT. Nevertheless, misdiagnosis of SREAT as degenerative ataxia
may have more clinical impact on patients, especially as no effective
treatment for degenerative ataxia is currently available. SREAT
patients who are misdiagnosed as having degenerative ataxia will miss
an opportunity for treatment and improvement; however, mistaking
degenerative ataxia for SREAT may lead to a trial of steroid, with no
improvement and subsequent reconsideration of the diagnosis. Cur-
rently, there are no specific clinical features or biomarkers other than
anti-TPO, anti-Tg antibodies, and steroid/immunotherapy respon-
siveness to differentiate SREAT from other degenerative ataxias.
We suggest searching for autoimmune etiologies including SREAT in
patients with subacute temporal profile of ataxia. However, in patients
with chronic ataxia, while we do not advocate routine tests for anti-
TPO and anti-Tg, SREAT should be kept when considering dif-
ferential diagnoses, especially if extensive investigations do not reveal
any degenerative etiologies.
FA may be included in the differential diagnoses for the present
patients, especially patient 1, who also had co-existing diabetes. How-
ever, our patients did not show other clinical features of FA includ-
ing macrosaccadic oscillations, hypo- (in classic FA) or hyperreflexia
(in late-onset FA). In addition, with regard to the natural history of FA,
diabetes usually develops many years after the onset of ataxia. In one
large series of 90 FA families, the mean duration of ataxia at the onset
of diabetes was 15.5 ¡ 6.82 years.24 One case report described a FA
patient who presented with type 1 diabetes.25 However, this patient
subsequently developed ataxia a year later. Our patient had diabetes
over 6 years before she developed ataxia. In addition, the subacute
time course of ataxia in both of our patients (3 and 6 months) initially
prompted workup for autoimmune etiologies (over degenerative
causes). Steroid responsiveness in both patients would also argue
against the diagnosis of FA. While it may not be totally unreasonable
to include FA genetic testing in our patients, this is unfortunately not
available.
In summary, identification of SREAT by anti-TPO and anti-Tg
testing, which may not be included in conventional ‘‘autoimmune
panels’’, should be considered as part of the workup of subacute and
chronic progressive cerebellar ataxia. This disorder is treatable with
immunotherapies, and therefore care must be taken not to misdiagnose
this entity as degenerative ataxia. While some patients with long disease
duration may still benefit from immunotherapies, diagnosis and treat-
ment should not be delayed, as in other autoimmune neurologic
disorders.26,27
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